News Column

CELL SOURCE, INC. FILES (8-K) Disclosing Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Results of Operations and Financial Condition, Changes in Registrant's Certifying Accountant, Unregistered Sale of Equity Securities, Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

July 1, 2014

Item 1.01 Entry into a Material Definitive Agreement.

On June 30, 2014 (the "Closing Date"), Cell Source, Inc. f/k/a Ticket to See, Inc. ("TTSE" or the "Company") entered into and closed a share exchange agreement (the "Share Exchange Agreement") with Cell Source Limited, a company incorporated in Israel ("Cell Source" or "CSL"), and 100% of the shareholders of CSL (the "CSL Shareholders") whereby CSL Shareholders, holding 18,245,923 of the outstanding shares of CSL, transferred an aggregate of 18,245,923 shares of Cell Source's ordinary shares, each of nominal value of NIS 0.01 ("CSL Ordinary Shares") to the Company in exchange for an aggregate of 18,245,923 newly issued shares of common stock, par value $0.001 per share, of the Company (the "Company Common Stock"). The aggregate of 18,245,923 newly issued Company Common Stock represents 78.5%% of the outstanding shares of common stock of the Company following the Closing Date. Outstanding warrants to acquire CSL Ordinary Shares were exchanged for newly issued warrants to purchase shares of the Company Common Stock (the "Company Warrants"). The Company Warrants contain substantially similar terms as the warrants to acquire CSL Ordinary Shares and entitle the holder to purchase an equivalent number of shares of Company Common Stock at an exercise price of $0.75 per share. The Company Warrants, which are subject to adjustment as provided therein, are redeemable by the Company at a price of $2.50 per share of Company Common Stock upon thirty (30) and sixty (60) days prior written notice to holders, subject to the conditions that (i) there is an effective registration statement covering the resale of the underlying shares of Company Common Stock and (ii) the Company Common Stock has traded for twenty (20) consecutive days with a closing price of at least $2.50 per share with an average trading volume of 100,000 shares per day. In addition, outstanding warrants to acquire CSL Ordinary Shares held by Dr. Reisner and Yeda (as defined below) were exchanged for warrants to purchase shares of Company Common Stock (the "Researcher Company Warrants"), which Researcher Company Warrants contain substantially similar terms as their warrants to acquire CSL Ordinary Shares. The Researcher Company Warrants entitle Dr. Reisner and Yeda to purchase 48,459 and 1,995,376 shares of Company Common Stock, respectively, at a price of $0.001 per share, subject to adjustment as provided therein, and may be exercised using a cashless exercise method.

In connection with the Share Exchange Agreement, holders of up to 15,000,000 CSL Ordinary Shares ("Certain Holders") and holders of up to 3,000,000 Company Common Stock ("Certain Company Holders" and, collectively with Certain Holders, the "Lockup Holders") are subject to a lockup agreement ("Lockup Agreement"), which terminates on the two (2) year anniversary of the Closing Date with . . .

Item 2.01 Completion of Acquisition or Disposition of Assets.

Information in response to this Item 2.01 is keyed to the Item numbers of Form 10.

Item 1. Description of Business.

Effective on the Closing Date, pursuant to the Share Exchange Agreement, Cell Source became a wholly-owned subsidiary of Ticket To See, Inc. The acquisition of Cell Source is treated as a reverse acquisition, and the business of Cell Source became the business of the Company. References to "we," "us," "our" and similar words refer to the Company and its subsidiaries after giving effect to the reverse acquisition. References to "TTSE" refer to the Company and its business prior to the reverse acquisition. Cell Source's corporate headquarter is located at 65 Yigal Alon Street, 23rd Floor, Tel Aviv 67433, Israel, and the telephone number at such address is (972) 3 562-1755. The Company's U.S. contact information is: 57 W. 57th St., Suite 400 New York, NY 10019 and (646) 416-7896.

Summary



Prior to merging with TTSE, Cell Source was a privately held company located in Tel Aviv, Israel. Cell Source was founded in 2011 in order to commercialize a suite of inventions that were the result of over ten (10) years of research at the Weizmann Institute of Science in Rehovot, Israel ("Weizmann Institute"). Pursuant to a Research and License Agreement by and between Cell Source and Yeda Research and Development Company Limited ("Yeda"), dated October 3, 2011, as amended on April 1, 2014 (the "Yeda License Agreement"), Yeda, the commercial arm of the Weizmann Institute, granted Cell Source an exclusive license to certain patents, discoveries, inventions, and other intellectual property generated (together with others) by Yair Reisner, Ph.D. ("Dr. Reisner"), head of the Immunology Department at the Weizmann Institute. Dr. Reisner is the inventor of the Megadose methodology that has been used for patients requiring "mismatched" or haploidentical donor bone marrow transplantation. Dr. Reisner was credited in the 1980's for effectively curing Severe Chronic Immune Deficiency ("SCID"), which is also known colloquially as the "boy in the plastic bubble disease." Currently, Dr. Reisner leads a team at the Weizmann Institute to continue the development of the technologies licensed to Cell Source in order to facilitate the technologies' transition from the laboratory to clinical trials. Cell Source also plans to collaborate with Dr. Herman Einsele and Dr. Franco Aversa, prominent figures in bone marrow transplantation, for cancer treatment and related research. Drs. Einsele and Franco plan to serve on our Scientific Advisory Board where they will oversee our initial clinical trials focusing on treating cancer through cell therapy accompanied by bone marrow transplantations.

4



Our lead prospective product is our patented Veto-Cell immune system management . . .

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

This Management Discussion and Analysis ("MD&A") contains "forward-looking statements", which represent our projections, estimates, expectations or beliefs concerning among other things, financial items that relate to management's future plans or objectives or to our future economic and financial performance. In some cases, you can identify these statements by terminology such as "may", "should", "plans", "believe", "will", "anticipate", "estimate", "expect" "project", or "intend", including their opposites or similar phrases or expressions.

You should be aware that these statements are projections or estimates as to future events and are subject to a number of factors that may tend to influence the accuracy of the statements. These forward-looking statements should not be regarded as a representation by the Company or any other person that the events or plans of the Company will be achieved. You should not unduly rely on these forward-looking statements, which speak only as of the date of this MD&A. Except as may be required under applicable securities laws, we undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this MD&A or to reflect the occurrence of unanticipated events. You should, however, review the factors and risks we describe under "Risk Factors" in this report. Actual results may differ materially from any forward looking statement.

Overview



Cell Source was founded in 2011 as a privately held company located in Tel Aviv, Israel, based on over ten (10) years of prominent research at the Weizmann Institute, the commercial arm of Yeda, from whom we license patented technology. Our exclusive, world-wide, license provides us with access to certain discoveries, inventions and other intellectual property generated by Dr. Reisner, Head of the Immunology Department at the Weizmann Institute, together with others. Dr. Reisner leads a team at the Weizmann Institute to continue the development of these technologies in order to facilitate the transition of those technologies from the laboratory to clinical trials. We also collaborate with Dr. Herman Einsele and Dr. Franco Aversa leading figures in bone marrow transplantation for cancer treatment and research, both of whom plan to serve on our Scientific Advisory Board and will oversee our initial clinical trials which, when started, will focus on addressing cancer through cell therapy accompanied by bone marrow transplants.

Our lead prospective product is our patented Veto-Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. The Company's target indications include lymphoma, multiple myeloma and BCLL, a form of leukemia treatment, facilitating . . .

Item 14. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

None. Item 15. Exhibits.



See Item 9.01 of this Current Report on Form 8-K.

Item 3.02 Unregistered Sales of Equity Securities.

See Items 1.01 and 2.01 of this Current Report on Form 8-K.

Item 4.01 Change in Registrant's Certifying Accountant.

Effective June 30, 2014, the Board of Directors of the Company dismissed Paritz & Company ("Paritz") as its independent registered accountant and engaged Marcum LLP ("Marcum") to serve as its independent registered accounting firm. Paritz's audit reports on the Company's financial statements for the fiscal years ended December 31, 2013 and 2012 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that, the audit reports included an an explanation with respect to the uncertainty as to the Company's ability to continue as a going concern. During the years ended December 31, 2013 and 2012 and during the subsequent interim period preceding the date of Paritz's dismissal, there were (i) no disagreements with Paritz on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, and (ii) no reportable events (as that term is defined in Item 304(a)(1)(v) of Regulation S-K). Prior to engaging Marcum, the Company did not consult with Marcum regarding the application of accounting principles to a specific completed or contemplated transaction, or the type of audit opinion that might be rendered on the Company's financial statements.

The Company has requested Paritz to furnish it with a letter addressed to the SEC stating whether it agrees with the statements made above by the Company. The Company has filed this letter as an exhibit to this Current Report on Form 8-K.

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

See Item 1.01 of this Current Report on Form 8-K.

Item 5.07 Submission of Matters to a Vote of Security Holders.



On June 30, 2014, the majority stockholder of the Company adopted resolutions approving the Share Exchange Agreement and the performance of all Company obligations thereunder, including the issuance of securities of the Company and the resignations, elections and appointments of the directors and officers as contemplated by the Share Exchange Agreement.

50



Item 9.01 Financial Statements and Exhibits.

(a) Financial statements of Cell Source are included following the signature page.

(b) Pro forma financial information. See Exhibit 99.1.

(c) Shell Company Transactions. See (a) and (b) of this Item 9.01.

(d) Exhibits Exhibit Number Description 2.1 Share Exchange Agreement, dated June 30, 2014, by and between Cell Source, Ltd., and Ticket to See, Inc. 3.1 Articles of Association of Cell Source Limited, dated August 14, 2011, as amended on November 11, 2013 10.1 Form of Subscription Agreement 10.2 Form of Registration Rights Agreement 10.3 Form of Investor Warrant 10.4 Form of Researcher Company Warrant 10.5 Form of Company Warrant 10.6 Form of Lockup Agreement (included in Exhibit 2.1) 10.7 Research and License Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited, dated October 3, 2011 10.8 Amendment to Research and License Agreement 10.9 Evaluation and Exclusive Option Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited, dated Oct. 3, 2011 (included in Exhibit 10.7) 10.10 Amendment dated April 1, 2014 to Evaluation and Exclusive Option Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited 10.11 Second Amendment dated June 22, 2014 to Evaluation and Exclusive Option Agreement by and between Yeda Research and Development Company Limited and Cell Source Limited 10.12 Consulting Agreement by and between Cell Source Limited and Professor Yair Reisner 16.1 Letter from Paritz & Company, P.A. 99.1 Pro forma financial information 99.2 Press Release dated July 1, 2014 51


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Edgar Glimpses


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters